文献速递细菌感染、耐药与抗菌药物结核与非结核分枝杆菌

麻风病抗菌药物耐药性:WHO监测网络2009-2015年前瞻性开放调查结果

Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009-15.
PubMed 文献 · Clin Microbiol Infect · 2018-03-01

2009至2015年,通过WHO监测网络对19个国家多菌型麻风病病例进行利福平、氨苯砜和氧氟沙星耐药基因检测,共研究1932例(复发1143例、新发789例),154株(8.0%)携带耐药突变,共182个耐药特征,利福平耐药在复发和新发病例中均出现,强调需扩大监测。

要点

  • 1932例中154株(8.0%)麻风分枝杆菌携带耐药突变,共182个耐药特征。
  • 利福平耐药见于复发(58/1143,5.1%)和新发(16/789,2.0%)病例,涉及12个国家。
  • 氧氟沙星耐药可能与其他感染中抗生素的普遍使用有关,需警惕全球抗菌药物使用。

核心结论

  • 这是首个报告麻风病抗菌药物耐药性全球数据的研究,利福平耐药已经出现,强调需要扩大监测。
  • 同时呼吁警惕全球抗菌药物使用,因为氧氟沙星耐药可能与其他感染中抗生素的普遍使用有关,氧氟沙星并非麻风病联合治疗方案的一部分。

研究设计与样本

  • 2009至2015年,通过WHO监测网络,在19个国家的哨点单位对多菌型麻风病病例进行研究。
  • 采用PCR测序检测rpoB、folP1和gyrA基因的耐药决定区,以确定对利福平、氨苯砜和氧氟沙星的耐药性。
  • 共研究1932例病例,包括1143例复发和789例新发病例。

主要发现

  • 1932例中154例(8.0%)麻风分枝杆菌菌株检出赋予耐药性的突变,共182个耐药特征:利福平74个、氨苯砜87个、氧氟沙星21个。
  • 20例显示利福平和氨苯砜耐药,4例显示氧氟沙星和氨苯砜耐药,未发现同时对利福平和氧氟沙星耐药的病例。
  • 利福平耐药见于复发(58/1143,5.1%)和新发(16/789,2.0%)病例,涉及12个国家。
  • 印度、巴西和哥伦比亚报告了超过5例利福平耐药病例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Antimicrobial resistance (AMR) is a priority for surveillance in bacterial infections. For leprosy, AMR has not been assessed because Mycobacterium leprae does not grow in vitro. We aim to obtain AMR data using molecular detection of resistance genes and to conduct a prospective open survey of resistance to antileprosy drugs in countries where leprosy is endemic through a WHO surveillance network. METHODS: From 2009 to 2015, multi-bacillary leprosy cases at sentinel sites of 19 countries were studied for resistance to rifampicin, dapsone and ofloxacin by PCR sequencing of the drug-resistance-determining regions of the genes rpoB, folP1 and gyrA. RESULTS: Among 1932 (1143 relapse and 789 new) cases studied, 154 (8.0%) M. leprae strains were found with mutations conferring resistance showing 182 resistance traits (74 for rifampicin, 87 for dapsone and 21 for ofloxacin). Twenty cases showed rifampicin and dapsone resistance, four showed ofloxacin and dapsone resistance, but no cases were resistant to rifampicin and ofloxacin. Rifampicin resistance was observed among relapse (58/1143, 5.1%) and new (16/789, 2.0%) cases in 12 countries. India, Brazil and Colombia reported more than five rifampicin-resistant cases. CONCLUSIONS: This is the first study reporting global data on AMR in leprosy. Rifampicin resistance emerged, stressing the need for expansion of surveillance. This is also a call for vigilance on the global use of antimicrobial agents, because ofloxacin resistance probably developed in relation to the general intake of antibiotics for other infections as it is not part of the multidrug combination used to treat leprosy.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Cambau E, Saunderson P, Matsuoka M, et al. Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009-15. Clin Microbiol Infect. 2018. PMID: 29496597. doi:10.1016/j.cmi.2018.02.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。